MarsiBionics
14
1
3
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Efficacy and Usability of the EXPLORER Exoskeleton in Children With Neurodevelopmental Disorders in Natural Environments
Role: lead
Safety, Usability, and Effectiveness of a Gait Exoskeleton for Children and Adolescents With Neurodevelopmental Disorders.
Role: lead
Safety and Usability of the ATLAS 2030 Exoskeleton in Pediatric Patients With Spinal Cord Injury
Role: lead
Safety and Usability of the EXPLORER Exoskeleton in Adults With Neuromuscular Diseases
Role: lead
Usability and Effectiveness of the ATLAS2030 Exoskeleton in Children With Cerebral Palsy
Role: lead
Safety and Usability of a Robotic Gait Device for Children and Adolescents With Neurological or Neuromuscular Disease in Their Natural Environment
Role: lead
Efficacy of a Rehabilitation Program With the Pediatric Exoskeleton ATLAS 2030 in Pediatric Patients With Cerebral Palsy
Role: lead
Proof of Concept of Pediatric and Adolescent EXPLORER V2 Exoskeleton in Children With Neurological and Neuromuscular Disease
Role: lead
Rehabilitative Effect of the Use of a Gait Exoskeleton in Patients With Neuromuscular Disease or Cerebral Palsy
Role: lead
Safety and Usability of the STELO Exoskeleton in People With Acquired Brain Injury and Spinal Cord Injury
Role: lead
MAKv1 Exoskeleton for TKA Patients: a Safety, Usability and Clinical Effects Trial of an Early Intervention
Role: lead
Exoskeleton Impact on the Quality of Life on Patients With Spinal Muscular Atrophy
Role: lead
Evaluation of the Safety and Usability of the MAK Exoskeleton in Patients With Stroke
Role: lead
Evaluation of the Exoskeleton ATLAS 2030 as Robot-assisted Physical Therapy to Children With Neuromuscular Diseases
Role: lead
All 14 trials loaded